As outlined in USP ⟨1114⟩ "Microbial Control Strategies for Cell Therapy Products," these biological products must not only ensure clinical safety and efficacy but also maintain rigorous protection against adventitious microbial contamination throughout their production lifecycle.
The unique nature of cell therapy products underscores the critical importance of microbial control during their manufacturing process. As outlined in USP ⟨1114⟩ "Microbial Control Strategies for Cell Therapy Products," these biological products must not only ensure clinical safety and efficacy but also maintain rigorous protection against adventitious microbial contamination throughout their production lifecycle. The World Health Organization explicitly defines such contaminants as including bacteria, fungi, mycoplasmas, viruses, and other microorganisms that may compromise patient safety or product effectiveness.
Since most cell therapy products cannot undergo terminal sterilization, their production must rely entirely on stringent aseptic processing standards. This challenge is particularly pronounced in autologous cell therapies, which typically involve small-scale, single-batch manufacturing with numerous open manipulations, significantly increasing contamination risks. For allogeneic therapies, while cell banking systems enable larger-scale production, the establishment of master and working cell banks still requires multiple layers of microbial containment.
Current regulatory frameworks provide clear guidance for these specialized products. The 21 CFR §1271 regulations mandate that human cell and tissue products comply with current Good Tissue Practices (cGTP), while the FDA's 2020 Gene Therapy IND Guidance further emphasizes the importance of aseptic processing. USP ⟨1046⟩ and ⟨1211⟩ offer technical references from the perspectives of product characteristics and sterility assurance principles, respectively. Notably, USP specifically recommends a risk-based quality management approach, identifying critical control points in the manufacturing process to focus limited resources on the highest-risk contamination areas, thereby balancing efficiency with safety.
It is important to note that due to USP's copyright restrictions, this text only summarizes key concepts. For complete standard requirements and implementation details, please refer to the official USP ⟨1114⟩ document.
Source: USP,The above content is for reference only. For more information, please click the original text:https://online.uspnf.com/uspnf/document/2_GUID-99DCB832-3046-40D5-8799-BE2F4A62C6C4_101010201_en-US?source=TOC
Cell Culture Flask